Gradient Investments
ORKA icon

Gradient Investments’s Oruka Therapeutics ORKA Stock Holding History

Gradient Investments’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,868
Closed -$273K – 489
2026
Q2 		$273K Buy
+2,868
New +$191K ﹤0.01% 417

Other funds holding ORKA

Secure Asset Management
Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
First Affirmative Financial Network
First Affirmative Financial Network Colorado Springs, Colorado $456M AUM
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Stone House Investment Management
Stone House Investment Management Tunkhannock, Pennsylvania $768M AUM 12.07% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Activest Wealth Management
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Gradient Investments's ORKA Position: Q3 2026 in Review

Gradient Investments sold out of Oruka Therapeutics (ORKA) in Q3 2026, closing a stake of 2,868 shares — an estimated $273K sold.

Gradient Investments first reported a position in ORKA in Q2 2026 and held it in 1 quarter. The position peaked at $273K in Q2 2026. 22 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

  • Gradient Investments reported no remaining Oruka Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Gradient Investments sold 2,868 Oruka Therapeutics shares in Q3 2026, an estimated $273K.
  • Gradient Investments first reported a position in Oruka Therapeutics in Q2 2026 and held it in 1 quarter.
  • Gradient Investments's Oruka Therapeutics position peaked at $273K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Gradient Investments's 13F filing for Q3 2026, filed 8 Oct 2026.